MarketPulse

minimally invasive

4 articles
BenzingaBenzinga··Prnewswire

IceCure's ProSense Cryoablation Gains Momentum as Q1 Revenue Surges 30%

IceCure Medical showcased ProSense® cryoablation at breast surgeons conference, reporting 30%+ Q1 revenue growth as adoption accelerates.
ICCMbreast cancerFDA clearance
BenzingaBenzinga··Prnewswire

IceCure's Kidney Cancer Data Shows Strong Promise Ahead of European Presentation

IceCure Medical reports positive 5-year results from ICESECRET trial, demonstrating 83.9% recurrence-free rates in kidney cancer patients using cryoablation technology.
ICCMclinical trialkidney cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Biocardia, Inc.

BioCardia's Helix Catheter Clears FDA Pre-Submission Milestone

BioCardia wins FDA acceptance of pre-submission package for Helix transendocardial delivery catheter, advancing minimally invasive cardiac therapy platform.
BCDAFDA approvalminimally invasive
BenzingaBenzinga··Prnewswire

ASBrS Endorses Cryoablation for Low-Risk Breast Cancer, Boosting IceCure Medical

ASBrS endorses cryoablation for low-risk breast cancer, validating IceCure Medical's ProSense system cleared by FDA in October 2025.
ICCMbreast cancerFDA clearance